Comparative Pharmacology
Head-to-head clinical analysis: CUBICIN RF versus MYCHEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CUBICIN RF versus MYCHEL.
CUBICIN RF vs MYCHEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Daptomycin is a cyclic lipopeptide antibiotic that binds to bacterial cell membranes, causing rapid depolarization and disruption of membrane potential, leading to cell death.
Mychel is a topical antifungal agent that inhibits ergosterol synthesis by binding to fungal cytochrome P450 14α-demethylase, disrupting fungal cell membrane integrity.
Adults: 6 mg/kg IV over 30-60 minutes every 24 hours. For deep-seated infections (e.g., endocarditis, osteomyelitis), consider 10 mg/kg IV every 24 hours.
Adults: 200 mg orally twice daily for 14 days.
None Documented
None Documented
Terminal elimination half-life: approximately 8-9 hours in patients with normal renal function; prolonged in renal impairment.
Terminal half-life: 8.5-12 hours (mean 10.2 h) in normal renal function; prolonged to 18-30 h in severe renal impairment (CrCl <30 mL/min)
Renal excretion: approximately 80% of the dose as unchanged drug; biliary/fecal elimination: minor (<5%).
Renal: ~70% unchanged; fecal: ~15% as metabolites; biliary: ~10%
Category C
Category C
Antibiotic
Antibiotic